In August 2021 Finfeed changed from a website that covered ASX listed news to a website
that covered a select range of ASX
listed small cap Biotech stocks that we are personally invested in: find out more.
The old Finfeed website, and all of the old articles are kept here for record keeping purposes.VISIT NEW SITE
CDY awarded US patent for treatment of alopecia, strengthening its hair loss treatment business
3 minute read
Cellmid (ASX:CDY) announced on Tuesday that the US Patent and Trademark Office had issued Notice of Allowance for the patent application number 14/464,358 entitled “Method of Treatment or Prevention of Hair Loss or for Enhancement of Hair Growth” (midkine or MK alopecia patent).
This development was well received by investors with the company’s shares rallying more than 7% in the first half hour of trading and maintaining that level well into the afternoon.
The midkine (MK) alopecia patent will expire in February 2031 and it adds to the significant intellectual property rights of Advangen Limited, Cellmid’s wholly owned subsidiary engaged in the commercialisation of hair loss technologies. Other Advangen patents relate to the evolis® products that act through the inhibition of the FGF5 protein to prevent hair loss and increase hair growth.
As a backdrop, Cellmid is an Australian life sciences company with prominent programs in multiple disease indications, and through its wholly-owned subsidiaries the company develops and markets innovative novel therapies and diagnostic tests for fibrotic diseases, cancer, ischaemic diseases of the heart and hair loss.
Yet being a speculative stock, there is no surety of future success and investors should seek professional financial advice for further consideration.
Cellmid has most comprehensive global portfolio of midkine and FGF5 IP
Importantly, the group holds the largest and most comprehensive portfolio of intellectual property relating to the unique targets midkine (MK) and FGF5 globally, IP that is being exploited through wholly-owned subsidiaries Lyramid and Kinera.
Cellmid’s total patent portfolio, commercialised by three of its wholly owned subsidiaries, currently comprises 75 patents and applications in 16 patent families including patents covering the use of MK and anti-MK agents for therapeutic purposes in a number of diseases such as cancer, inflammatory conditions and autoimmune diseases.
Advangen, Cellmid’s consumer health business sells its FGF5 inhibitor hair growth products in Australia and Japan.
MK alopecia patent to complement those already granted in Japan, Australia and the UK
The MK alopecia patent complements other members already granted in the patent family in Japan, Australia and the UK providing broad geographical protection over the use of the MK protein for the treatment of a number of conditions resulting in hair loss.
The alopecia patent also adds to the key patent families that ensure the company’s dominant intellectual property position over the treatment of inflammatory, ischaemic and autoimmune diseases, cancer and bone disorders by targeting or using MK.
Results presented in the current patent show that MK prevents hair follicles entering catagen, likely through anti-apoptotic action. As has been shown in other organs where MK prevents tissue injury associated with several diseases, it may help in the treatment of hair disorders by enhancing the protective and regenerative cell processes in the hair follicle.
Cellmid’s chief executive Maria Halasz said one form of alopecia for which MK may be particularly useful is acute hair loss caused by chemotherapy. Hair loss is a common side effect associated with cytotoxic agents used in the treatment of cancer and causes considerable anxiety and loss of self-esteem for many cancer patients.
Pre-clinical experimental evidence has shown that treatment with MK either prior to or during chemotherapy resulted in faster hair regrowth than for placebo treated subjects. Such findings pave the way for clinical trials in cancer patients. If successful, midkine-based treatment for hair loss may be of considerable benefit for many of these patients at the crucial stage of remission.